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Summary: Asialoglycoproteins injected into the tail vein of mice accumulated rapidly in the liver, as found in rats
and rabbits by other authors, whereas the native glycoprotein remained In the serum for much longer periods of time.
Histological examination of liver sections after the injection of radiolabelled asialoglycoproteins failed to show any
binding to the hepatocyte membrane. However, silver grains were observed in the sinuses of the liver and often
appeared to be bound to the sinus wall. In addition, small amounts of label in the reticulo-endothelial system of the
spleen were observed.
A comparison in the uptake of asialoglycoproteins by the liver, between those with alkali-labile galactose-containing
(AL) chains and those with alkali-stable galactose-containing (AS) chains, showed that the former were taken up
more slowly. There was no correlation between total galactose content and rate of hepatic uptake.
Asialoglycoproteins with AS chains could not inhibit the uptake in the liver of those with AL chains. However, when
the order was reversed, the uptake of AS containing asialoglycoproteins was. inhibited by 50 %. Different mechanisms
to explain these results are discussed.
Untersuchungen über das Schicksal definierter Asialoglykoproteine im Kreislauf der Maus
Zusammenfassung: Asialoglykoproteine, welche in die Schwanzvene von Mäusen injiziert wurden, akkumulierten
sehr schnell in der Leber, was auch von änderen Autoren bei Ratten und Kaninchen gefunden worden ist, wohin-
gegen das native Glykoprotein für einen viel längeren Zeitraum im Serum verweilte.
Histolpgische Untersuchungen an Lebersehnltten nach der Injektion von radioaktiv markierten Asialoglykoproteinen
zeigten allerdings keine Bindung an der Hepatocytenmembran, jedoch konnten Silberkörnchen in den Lebersinus
beobachtet werden, die oft an den Sinuswall gebunden zu sein schienen. Außerdem wurden kleine Mengen an mar-
kierter Substanz in dem retlkulo-endothelialen System der Milz festgestellt.
^Present address:




©by Walter de Gruyter & Co. - Berlin - New York
32 Newman, Fricke, Klein, Uhlenbruck and De Vries: The fate of defined asialoglycoproteins in the circulation of the mouse
Ein Vergleich hinsichtlich der Aufnahme von Asialoglykoproteinen durch die Leber wurde in Bezug auf solche mit
alkali-labilen, galaktosehaltigen (AL) Ketten und solche mit alkalistabilen galaktosehaltigen (AS) Ketten durchge-
f hrt, wobei sich herausstellte, da die ersteren viel langsamer aufgenommen wurden. Es ergab sich aber keine Korre-
lation zwischen dem Gesamt-Galaktosegehalt und der Rate der Aufnahme durch die Leber.
Asialoglykoproteine mit AS-Ketten konnten die Aufnahme in die Leber von solchen mit AL-Ketten nicht inhibieren.
Jedoch in umgekehrter Reihenfolge konnte die Aufnahme von Asialoglykoproteinen mit AS Ketten zu 50 % gehemmt
werden. Diesen Ergebnissen liegen wahrscheinlich verschiedene Mechanismen zugrunde.
Introduction
Removal of sialic acid from many glycoproteins followed
by intravenous injection results in a rapid uptake by the
liver and subsequent removal from the serum (1,2). This
is in contradistinction to the native glycoprotein which
remains in the serum for long periods of time. The
mechanism whereby asialoglycoproteins are sequestered
in the liver has been shown to be dependent, in mammals,
on the integrity of terminal Z^-galactosyl residues, which
are usually exposed after removal of terminal sialic acid
(1). In birds there appears to be a comparable system
involving terminal N-acetyl-Z)-glucosamine (3).
In addition to a galactose-specific recognition system in
mammalian liver, there is some evidence that rats may
possess receptors for Z)-mannose and N-acetyl-/)-glucos-
amine on the Kupffer cell surface in the liver (4). L-
Fucose will also compete with these two latter mono-
saccharides for uptake by the liver (4), suggesting that
either there are several recognition systems involving
different sugars or that a single receptor exists which is
unable to distinguish between various glycosyl con^·
figurations. Galactose, however, does not affect the up-
take of mannose or N-acetyl-glucosamine suggesting a
distinct receptor for this monosaccharide, although it
has been shown that the D-galactose receptor cannot
distinguish between the galactosyl and glucosyl confi-
gurations (5).
Asialoglycoproteins usually possess terminal D-galac-
tosyl residues, which in turn are linked usually to N-
acetyl-glucosamine or N-acetyl-galactosamine via a
/Jl-4 or 01-3 linkage respectively (6). These two types
of linkages are often indicative of the carbohydrate
chain involved. For example, carbohydrate chains of
the so-called serum type are usually branched, linked to
protein via an N-acetyl-glucosamine/asparagine bond,
contain mannose and often have the terminal sequence















smaller mucin type of chain has an alkali-labile N-acetyl-
galactosamine/serine or threonine linkage to the protein
backbone, does not contain mannose and often has the
terminal sequence Ν AN A,Gal(j31-3)-GalN Ac (GalNAc
can also be substituted by NANA) (8j). Investigations
into the fate of asialo serum glycoproteins, which con-
tain both of these types of carbohydrate chain, may be
affected therefore not only by the presence of terminal
Z)-galactosyl residues but also by the influence of the
sub-terminal sugar and its linkage.
The fate of asialoglycoproteins with the terminal sequence
Gal(j31— 3)GalNAc. . . is especially interesting as it has
been shown that there exists, in most mammals, a
naturally occurring antibody directed against this struc-
ture (9,10). This study was undertaken therefore to
examine the clearance of asialoglycoproteins in which
the terminal galactosyl residues are present as part of a
serum type (alkali-stable) or the mucin (alkali-labile)
type of carbohydrate chain and also whether separate
mechanisms exist for their removal from the serum.
Experimental
Materials
An inbred strain of MRI mice originally purchased from the
S ddeutsche Versuchstier-Farm, Tuttlingen were used in all
experiments. Human coeruloplasmin, cholinesterase, oroso-
mucoid (<*! acid-glycoprotein), haptoglobin, 02 Hi glycoprotein,
lactofenin as well as Vibrio choleras neuraminidase (E.G.
3.2.1.18, 500 units/ml) and all general chemicals were ob-
tained from Behringwerke (Marburg/Lahn, F.R.G.).
Antifreeze glycoproteins from the Antarctic fish Trematomas
borchgrevinki with molecular weights of between 10,500 and
23,500 were isolated as described previously by De Vries et
Galactose oxidase (E.G. 1.1.3.9) was obtained from Sigma Ltd.,
and tritiated acetic anhydride from NEN Chemicals (specific
activity 370 GBq/mmol). Sodium borotritiide (specific activity
740 GBq/mmol) was obtained from Amersham/Searle.
Methods
Desialylation of glycoproteins
Glyeoproteins (4.5 mg) were dissolved in phosphate buffered
saline (1 ml) and incubated for 24 h at 37 °C with 40 units of
neuraminidase in the presence of 10 mmol/1 sodium azide at
pH 5.6*Preluninary experiments with all the glycoproteins
used showed that these conditions were sufficient to release all
the sialic acid. Antifreeze glycoprotein was the only exception
as it did not contain any sialic acid.
Alternatively, glycoproteins were incubated for l h at 80 °C in
the presence of 0.05 mol/1 Η2$Ο4, after which the solution was
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cooled and neutralised with Dowex-1 resin (-OH'form). The
resin was removed by centrifugation and the supernatant either
stored at -20 °C or lyophilised then stored. Although identical
results were obtained with either method, treatment with low
concentrations of neuraminidase was preferred.
Monosaccharide analysis of glycoproteins
Monosaccharide analysis was carried out as previously described
(12). Briefly, glycoproteins (1 mg/ml) were incubated with
3 mol/1 HC1 at 100 °C for 4 h, after which the solution was
neutralised with silver carbonate. The precipitate of silver
chloride was removed by centrifugation. The supernatant and
washings were lyophilised, reacetylated (13) and trimethylsilyl
derivatives prepared for chromatography (12). An internal
standard of £-erythritol (30 Mg) was included before hydrolysis
and the trimethylsilyl-monosaccharides measured by gas chro-
matography on columns of 3 % OV-17 and 3 % SE-30 on
Chromasorb Q (80-100 mesh, Serva).
Sialic acid was not routinely determined by gas chromatography
but by the method of Aminoff after hydrolytic release in 0.05
mol/1 H2SO4 at 80 °C for l h (14).
Removal and measurement of the alkaline-labile disaccharide
-D-galact osy 1(1 —3) -N-acetyl-D-galactosamine
Glycoproteins (1 mg) were incubated at 37 °C for 24 h with
0.05 mol/1 NaOH containing 1.0 mol/1 NaBH4 and then neu-
tralised with Dowex 50 resin (-H*-form). The supernatant was
removed and the resin washed with water. Supernatant and
washings were combined, lyophilised and trimethylsilyl deri-
vatives prepared for gas chromatography in the same way as
for monosaccharides. Before alkaline borohydride treatment,
glycoproteins were either desialylated by acid hydrolysis or
left untreated in order to determine the amount of disaccharide
unsubstituted by sialic acid as well as the total amounts. An
internal standard of trehalose was included (30 μΐ).
Radiolabelling of glycoproteins
Two methods were used for the radiolabelling of glycoproteins;
the galactose oxidase/NaB H4 technique, in which carbohydrate
residues could be labelled arid direct acetylation of the protein
chain. For the former method, glycoprotein samples were
desialylated as described and then incubated for 20 h at 25 °C
with 10 units of galactose pxidase. After oxidation, glycopro-
teins were reduced by addition of 37-74 MBq of NaB3H4 and
incubation at room temperature for 30 min. Reduction was
completed by adding excess non-tritiated NaBH4 (10 mg) with
further incubation for 15 min. The glycoproteins were dialysed
against phosphate buffered saline (3 X 51), concentrated and
volumes adjusted. If not used immediately the aliquots were
stored at -20 PC.
The second method of radiolabelling was acetylation with tri-
tiated acetic anhydride as has been previously described (15).
Injection of mice
Varying concentrations of radiolabelled glycoprotein were in-
jected intravenously into mice via the tail vein. After injection
the mice were killed by anaesthetising with ether followed by
exsanguinatipn and cervical dislocation. This was carried out at
periods between 1 and 30 min after injection. Liver, kidney,
spleen, blood and urine were routinely removed but in addition
from some mice brain, skeletal muscle, heart, lung and bone
marrow were also examined. Each organ was weighed imme-
diately after removal, a portion fixed for histological staining
and approximately 100 mg taken for radioactive counting.
Measurement of radioactivity in tissues
Organs which were to be counted were cut into small pieces in
a glass counting vial and 1 ml of 'NCS Tissue Solubiliser* (Amers-
ham/Seaile, England) added. The samples were then left at
40 °C overnight or until the tissue was completely digested. Any
discoloration was removed by briefly heating in the presence of
a drop of hydrogen peroxide. Scintillant was added and the
samples counted. Radioactivity was expressed as counts/min · g
of fresh tissue or as counts/min per whole organ.
Inhibition of glycoprotein uptake
Inhibition experiments were carried out to examine the effect
of asialoglycoproteins containing the disaccharide 0-Gal(l-3)
GalNAc on the uptake of asialoglycoproteins that do not con-
tain this disaccharide and vice versa. This was done by injection
of a non-labelled glycoprotein followed by a second labelled
asialoglycoprotein. The second glycoprotein was injected at the
time when the first glycoprotein had reached maximum uptake
in the liver, usually 10—15 min. The organs were then excised
10—15 min after the injection of the second glycoprotein and
counted as described above.
Histology
Tissue (ca. 100 mg) removed as described above was fixed in
60 g/1 formaldehyde and, after embedding in paraffin wax,
sectioned, stained by conventional histochemical staining tech-
niques and then prepared for autoradiography. This was carried
out by overlaying the preparation with K2 Emulsion (Ilford)
and exposing the samples for 8-15 days before development.
Results
Analysis of glycoprotein mono and disaccharide
content
The amounts of monosaccharides present in the various
glycoproteins together with the amount of alkali-labile
disaccharide 0-Z?-galactosyl-l -3)-N-acetyl-Z)-galactos-
amine is summarised in table 1.
It can be seen that cholinesterase and /32IH glycoprotein
both contain the above disaccharide and also are the only
glycoproteins to possess N-acetyl-galactosamine residues.
In addition they contain some mannose and N-acetyl-
glucosamine suggesting the presence of both alkali-labile
(AL) and stable chains (AS). Lactoferrin, haptoglobin,
orosomucoid and ceruloplasmin contained relatively
higher amounts of mannose and N-acetyl-glucosamine,
in relation to the total carbohydrate, and no alkali-labile
material suggesting that the carbohydrate is present in a
serum-type (AS) oligosaccharide chain. Antifreeze glyco-
protein was not subjected to analysis because of the
small amounts available but it is known from previous
data that only galactose and N-acetylgalactosamine are
present in a 1:1 ratio and this is linked at every third
amino acid in the peptide chain as |3-£)-galactosyl(l —3)-
N-acetyl-£>-galactosamine (16,17,18).
The fate of injected asialoglycoproteins
Removal of 100 % of sialic acid prior to injection resulted
in a rapid removal of asialoglycoproteins from the serum,
which were then taken up by the liver. Maximum label
in the liver was found after 10—15 min after which it
decreased to less than 50% of maximum approximately
30 min later. The gradual decrease in the amount of
radioactivity in the liver could not be detected as an
increase in serum levels, although the amount found in
the kidney and especially the urine steadily increased.
The radioactivity in the urine was difficult to quantify
as the volume in the bladder was different with each
mouse.
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Fig. 1. Uptake of 3 H by the liver at various times after injection
of asialo and native 3H-aracid glycoprotein. *
ο—ο Native AI acid giycoprotein; ·—· Asialo aj acid
glycoprotein; ·—· cq acid glycoprotein minus 25% of
the total sialic acid.
Removal of only 25 % of the sialic acid also resulted in
uptake by the liver although the peak of maximum up-
take occurred about 10 min later (fig. 1). When native
glycoproteins were injected no uptake was seen in the
liver and serum levels fell only slightly over a 30 min
period.
No difference in distribution or uptake were found
whether glycoproteins were labelled by galactose
oxidase/NaBH4 or by acetylation. This indicated
that the carbohydrate parts of the glycoprotein mole-
cule were not cleaved in vivo and not the explanation
for the decrease in radioactivity in the liver after the
maximum peak. As a higher specific activity could be
obtained with the direct acetylation technique, this was
therefore used for most experiments. Antifreeze glyco-
protein was always labelled by the galactose oxidase
technique, however.
Tissue distribution of injected glycoproteins
With the exception of antifreeze glycoprotein, counting
of tissue digests from various organs showed that after
injection of asialoglycoproteins most of the radioactivity
was localised in the liver. The kidney (and urine) was the
only other organ to accumulate any significant activity.
The number of counts in the kidney was low in com-
parison to the liver, although this increased when higher
amounts of glycoproteins were injected. Antifreeze
glycoprotein and |32 HI glycoprotein gave higher recoveries
in the kidney than the other glycoproteins, however. This
was probably due to their lower molecular weights (fig. 2).
After injection of antifreeze glycoprotein some activity
was measurable in the lung. This was not observed with
any other glycoprotein.
Native A! acid glycoprotein . Asialo 04 acid glycoprotein
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Fig. 2. Distribution of 3H in various tissues 10 minutes after
injection of native and asialo glycoproteins.
For asialo glycoproteins the liver value is fixed at 1.00.
For native glycoglycoproteins serum levels are fixed at
1.00.
L = liver; S = serum; K = kidney; Sp = spleen; U = urine;
M = muscle; H = heart; Lu = lung; B = bone marrow.
Histological findings
Liver, spleen, bone marrow and heart tissue from mice
which had been injected with asialoglycoproteins were
examined by autpradiography. Only liver sections showed
distinct localised areas of labelling although small
amounts of label were present on cells of the reticulo-
endothelial system in the spleen. Although labelling was
detected in the spleen using autoradiography, it was not
measurable when pieces of spleen were digested and
counted directly in a scintillation counter.
Silver grains in liver preparations were found mainly
in the sinus (fig. 3). No direct evidence for the binding
of asialoglycoproteins to Kupffer cells was obtained,
however, areas associated with these cells showed the
presence of radiolabelling. Throughout the experimental
time course of 30 min, no direct binding to hepatocytes
was observed.
Labelling was only seen on the sinusoidal side of the
sinus wall. When antifreeze glycoprotein was injected,
traces of silver grains were sometimes observed on the
surfaces of erythrocytes within the hepatic capillaries.
Effect of chain type on uptake of glycopTOteins
Prom table 1 it can be seen that lactoferrin, haptoglobin,
orosomucoid and ceruloplasmin contain no alkali labile
disaccharide whereas cholinesterase and j32IH glyco-
protein probably contain both types of chain. Antifreeze
glycoprotein, however, contains only the alkaline labile
disaccharide. Injection of the first four glycoproteins
all gave kinetics of uptake similar to that shown in
figure 1. Antifreeze glycoprotein was taken up by the
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Fig. 3a/b. Autoradiograph of a liver section 10 minutes after injection of 3H-antifreeze glycoproteins.
Silver grains can be observed in the sinuses (arrow).
Tab. 1. Monosaccharide and disaccharide analysis of glycoproteins used in uptake experiments


































































liver more slowly. The peak of maximum uptake was
consistently observed to be about 5 min later than that
of the first four glycoproteins. This did not appear to
be related to either the concentration of glycoprotein
used or to the amount of galactose in the glycoprotein.
Both cholinesterase and j32 ΪΠ glycoprotein fell between
these two extremes (fig. 4).
Inhibition of the uptake of lactpferrin by anti-
freeze glycoprotein
Injection of asialororpsomucoid followed by antifreeze
glycoprotein did not affect the uptake of the latter.
Similarly prior injection of asialolactofeitin also had no
effect on the uptake of antifreeze glycoprotein. By
reversing the order of administration it was found that
antifreeze glycoprotein could inhibit the uptake of asialo-








Fig. 4. Uptake of 3 H by the liver after injection of asialo giyco-
proteins with different carbohydrate chains.
Uptake is expressed as a percentage of the maximum
uptake.
·-—· Asialo lactoferrin; *—* Asialo α ι acid glyco-
protein; ο—ο Asialo ^lll serum glycoprotein;
ι Antifreeze glycoprotein.
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Tab. 2. Inhibition of uptake of 3H-labelled asialo glycoproteins by the liver by non-labelled asialo glycoproteins with different carbo-
hydrate chain type
1 st Glycoprotein 2nd Glycoprotein
Counts/inin · g fresh tissue or**
Counts/min · ml serum
Liver Serum Kidney
10 μ§ antifreeze glycoprotein*
100 Mg antifreeze glycoprotein*




100 Mg antifreeze glycoprotein
100 Mg antifreeze glycoprotein
_
-
10 Mg antifreeze glycoprotein*





























* indicates radiolabelled glycoprotein.
** Mean values from 5 animals; for further details see Ute Fricke, Thesis, Medical Faculty, University of Cologne, 1979.
Discussion
The aim of this work was to investigate the fate of asia-
loglycoproteins with different types of galactose-contai-
ning carbohydrate chains, after intravenous injection into
mice. The majority of the labelled material was removed
very rapidly from the serum and concentrated in the
liver in a manner similar to that demonstrated in rats by
Gregoriades et al. (19). Removal of only a part of the
total sialic acid resulted in a slower rate of uptake by
the liver, reaching a maximum approximately 5 minutes
later after 25 % of the sialic acid had been removed, for
example.
The kinetics of uptake of asialoglycoproteins by murine
liver were similar to those in the rat, as reported by other
authors (19,20). After approximately 30 minutes the
levels had returned almost to basal level, suggesting
that it was being re-released into the serum or metabo-
lised. No significant radioactivity was found in the serum
after this time, however, and the increased amounts in
kidney and urine would support the latter hypothesis.
Apart from that found in the kidney (and urine) the
majority of radioactivity was found in the liver, when
measured by scintillation counting of tissue digests.
j32 III serum glycoprotein and antifreeze glycoprotein
appeared in the kidney and urine in higher amounts
than any of the other glycoproteins tested, which may
be a reflection of the lower molecular weights of these
glycoproteins, enabling them to pass directly through
the glomerular membrane without prior binding and
metabolism in the liver. When higher amounts of glyco-
proteins were injected, the distribution was identical
except that some of the antifreeze glycoprotein localised
in the lung. Whether this was due to the presence of a
receptor in the lung or whether it is the result of binding
of immune complexes to elements of the reticulo-endo-
thelial system (RES) in the lung, is not known.
Examination of autoradiographs of liver sections
removed at varying intervals after the injection of
asialoglycoproteins suggested that, over a period of 30
minutes, there was no evidence that binding to hepato-
cytes had occurred. This is in contrast to the findings
ofMorell et al. (1) who reported exclusive .binding to
the hepatocyte. Labelling was only seen on the sinusoidal
side of the sinus wall and at no time had crossed this
wall. Binding to the other major cell in the liver, the
Kupffer cell, was not directly shown, although localised
concentrations of label on the sinus wall around the
site of these cells was often observed. Kolb & Kolb-Bach-
ofen (21) have suggested that soluble asialoglycoproteins
as well as asialo cells may be taken up by Kupffer cells.
The evidence of small amounts of label in the RES of
the spleen would seem to support this suggestion. Van
Rijk & van den Hamer (20) have also reported small
accumulations of asialo o^ acid glycoprotein in rat
spleen after 20 minutes.
The elegant series of experiments ofMorell, Ashwell
and coworkers (1,2,22,23,24) have clearly shown that
a hepatic receptor can be isolated from rats and rabbits
which binds asialoglycoproteins selectively and with
high affinity in vitro. The results of our experiments,
however, have failed to show that asialoglycoproteins,
when injected into mice and examined hfetologically,
come into contact with the hepatocyte or indeed cross
the sinus wall. However, our biochemical measurements
support the existence of a receptor for asialoglycopro-
teins in the liver.
A comparison of glycoproteins with AL galactose con-
taining chains with those containing AS-galactose chains
did not in general show any differences in distribution,
with the exception of the finding described above in the
lung after high levels of antifreeze glycoprotein. Glyco-
proteins with AS carbohydrate chains were consistently
found to be taken up by the liver more rapidly than
those with AL carbohydrate chains. This, however, was
not dependant on the total amount, of galactose present.
Greater numbers of residues per glycoprotein molecule
did not necessarily mean a faster rate of uptake.
J. Ciin. Chem. Clin. Biochem. / Vol. 18,1980 / No. 1
Newman, Fricke, Klein, Uhlenbruck and De Vries: The fate of defined asialoglycoproteins in the circulation of the mouse 37
The possibility of more than one type of receptor specific
for galactose has previously been postulated (21) and,
although Ashwell &Morell examined the competitive
inhibition between asialo-orosomucoid and asialo-cerulo
plasmin, the existence of different receptors for glyco-
proteins with different carbohydrate chains was not
considered. Our results, using glycoproteins with AL
chains to compete with those possessing AS chains
suggested that this could be the case although the results
can also be explained by other mechanisms. The four
main possibilities are as follows:
1. A single receptor exists and that a terminal galactose
residue linked 01 — 3 to GalNAc is in a better con-
formation to bind than one linked via a 01—4 linkage
to GlcNAc.
2. The galactose receptor may have an extended site i.e.
one of which galactose is only part and where a second
sugar also plays a role. GalNAc may fulfil this function
better than GlcNAc.
3. Two receptors may be present both of which bind
galactose in the 01—3 linked conformation but only
one of which binds galactose residues in the ]31 -4
linked conformation. Thus prior injection of anti-
freeze glycoprotein (which has a 01— 3 linkage) would
block both receptors whereas prior injection of asialo-
lactoferrin or asialo-orosomucoid would only block
one, not therefore affecting the binding of antifreeze
glycoprotein.
4. The in vivo role of anti-TF can be considered. It is
known that antifreeze glycoprotein will bind anti-TF
(17) although asialolactoferrin or asialo-ceruloplasmin
will not (unpublished results). It is possible therefore
that glycoproteins containing the disaccharide Gal
031 —3)GalNAc will form immune complexes in vivo
which are then bound by cells in the liver (or other
cells of the RES). Thus, antifreeze may bind partly
to liver cells via terminal galactose residues and partly
as immune complexes. Asialo-orosomucoid and asialo-
lactoferrin will only bind via terminal galactose residues
however. Prior injection of asialo-lactoferrin would
therefore not inhibit the binding of immune com-
plexes but antifreeze may compete for the latter's
binding site as well as forming an immune complex.
The true nature of the binding of different glycoproteins
is not possible without further investigation but we have
endeavoured to show that the assumption that asialo-
glycoproteins bind to cells in the liver solely by virtue
of their exposed galactose residues may not be the only
explanation. Consideration of the type of carbohydrate
chain and careful histological examination is a necessary
requirement for the investigation of the fate of asialo-
glycoproteins in vivo.
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